Long and costly product development cycles make it essential today for pharmaceutical companies to allocate resources to the development of compounds with the greatest potential market value. Leading companies are integrating commercial insights early in the new-product process to identify and eliminate unpromising compounds, reduce development cycle time, focus resources for greatest impact and increase their potential for launching a blockbuster drug. This Best Practices Benchmarking® report provides crucial insights into developing successful early-stage commercialization and portfolio management programs. Through this report, you can gain a thorough understanding of how industry-leading companies manage early-stage (pre-clinical through Phase II) commercialization. Winning strategies, structures and practices of top companies in developing early-stage product commercialization and portfolio management functions are identified and examined in detail.